Bulevirtide Acetate

N/A

Report date: 2026/05/25 20:02:40
NMEFirst In Class

Base Information

Drug NameBulevirtide Acetate
Drug Alias NameMyrBMyrcludex-BBulevirtideBulevirtide-gmodHepcludex +[8] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionSodium/bile acid cotransporter bindersHBV DNA Polymerase modulators
TargetsHBV DNA PolymeraseSodium/bile acid cotransporter
Therapy Area/IndicationsHepatitis, ChronicHepatic InsufficiencyHepatitis D, Chronic +[5] 
Global Approved IndicationsHepatitis D, Chronic
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2020/07/31
Country/TerritoryCzechiaUnited StatesSweden +[13] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesInsermUniversity Of Heidelberg
China Registration ClassN/A

Develop Information

Active CompaniesGilead Sciences IncGilead Sciences Ireland UcMirum Pharmaceuticals Inc
Inactive CompaniesHepatera Ltd
Active IndicationsHepatitis, ChronicHepatic InsufficiencyHepatitis D, Chronic +[4] 
Inactive IndicationsHepatitis B, Chronic

Other Information

ATC CodeJ05A
Related LinksWikipediaDrugBank